作者
Di Wu,Jing Li,Dong Xu,Joan T. Merrill,Ronald van Vollenhoven,Yi Liu,Jiankang Hu,Jing Wang,Fen Li,Chenghui Huang,Guochun Wang,Xiaomei Li,Jianhong Zhao,Dongbao Zhao,Cibo Huang,Huaxiang Liu,Wei Wei,Guixiu Shi,Fuai Lu,Xiaoxia Zuo,Liqi Bi,Zhijun Li,Xiaoxia Wang,Shouxin Zhang,Ning Tie,Juan Li,Hanyou Mo,Jianmin Fang,Chunde Bao,Fengchun Zhang
摘要
This phase 2b, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of telitacicept, a novel fusion protein that neutralises signals of B lymphocyte stimulator and a proliferation-inducing ligand, in active systemic lupus erythematosus (SLE).